Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,635 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia; Psychosis Clear all
Not listed Phase 2 Interventional

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

NCT00725855
View directory record Official record
Conditions
Schizophrenia
Interventions
MEM 3454, Placebo for MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Jun 10, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Timing of Voluntary Movement in Patients With Schizophrenia

NCT00080548
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Schizophrenia Study In Adults

NCT00049946
View directory record Official record
Conditions
Schizophrenia
Interventions
talnetant, risperidone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
31
States / cities
Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Reducing Internalized Stigma in People With Serious Mental Illness

NCT01259427
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jun 10, 2026, 10:03 AM EDT
Recruiting Phase 4 Interventional

Biomarkers to Enhance Early Schizophrenia Treatment

NCT06969755
View directory record Official record
Conditions
Schizophenia Disorder
Interventions
aripiprazole, risperidone, clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
La Jolla, California • Belmont, Massachusetts • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Bioavailability of Oral Formulations of Vabicaserin

NCT00541996
View directory record Official record
Conditions
Schizophrenia
Interventions
vabicaserin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Jun 10, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional

5HT3 Antagonism and Auditory Gating in Schizophrenia

NCT00018850
View directory record Official record
Conditions
Schizophrenia
Interventions
ondansetron, neuropsychological testing, nicotine, haloperidol
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jun 10, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

NCT03230097
View directory record Official record
Conditions
Psychotic Disorders
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
16 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Culver City, California • San Diego, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

NCT00320723
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
bupropion, transdermal nicotine patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effects of Mecamylamine and Varenicline in Schizophrenia

NCT00455650
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Mecamylamine, Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 68 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Jun 10, 2026, 10:03 AM EDT
Active, not recruiting Not applicable Interventional

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

NCT05756855
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder, Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
adapted behavioral intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
16 Years to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jun 10, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional

Digital Strategies to Advance Help-Seeking - Aim 3

NCT06774417
View directory record Official record
Conditions
Clinical High Risk, Early Psychosis, First Episode Psychosis
Interventions
Digital nudge
Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 29 Years
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Pharmacological Approach to Improve the Outcome of Social Cognition Training

NCT01517360
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Social Cognitive Skills Training
Drug · Other · Behavioral
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT00136760
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

NCT00145847
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Alcohol Abuse, Alcoholism, Alcohol-related Disorders
Interventions
Naltrexone or Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

NCT06179108
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Once-monthly in Patients With Schizophrenia

NCT01959035
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole once-monthly
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

Clozapine for Cannabis Use in Schizophrenia

NCT01639872
View directory record Official record
Conditions
Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis
Interventions
Clozapine, Risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Garden Grove, California • Oakland, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

NCT00590577
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Appeal and Impact of E-cigarettes in Smokers With SMI

NCT03050853
View directory record Official record
Conditions
Tobacco Dependence, Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
Interventions
E-cigarette
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Louisville, Kentucky • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

NCT03201757
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
49
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jun 10, 2026, 10:03 AM EDT